Zimbabwe skipper Graeme Cremer claimed three wickets to dent Sri Lanka's first innings reply on the second day of the one-off Test in Colombo on Saturday (15).
Cremer's leg-spin and two crucial run outs left Sri Lanka reeling at 293-7 at stumps. Asela Gunaratne (24) and Rangana Herath (5) were at the crease with the hosts still trailing Zimbabwe by 63 runs.
Gunaratne, who came down the batting order at number eight after sustaining a hamstring injury while fielding, put up sturdy resistance in the final few overs of the day.
"The wicket has got drier and the leg-spinner (Cremer) is taking lot of turn. We have to bat well and we need to make sure that we get to 350," said Herath, who had taken five wickets to help dismiss Zimbabwe for 356.
"We had a good start, but they fought back well. We are still behind by 63 runs and we need to knock off that deficit," Herath told reporters.
Zimbabwe coach Heath Streak believes the visitors are in a "nice position", adding that anything between 250 and 280 would be a tough fourth-innings chase on this pitch.
"Any sort of lead is going to be very valuable on this track. It's going to be an interesting day's play tomorrow. Hopefully we can pick up those wickets quickly," Streak said.
Top Sri Lankan batsmen faltered against Cremer's wily wrist spinners including captain Dinesh Chandimal falling to his opposite number after a well-made 55.
Chandimal's wicket ended a 96-run stand for the fourth wicket with Angelo Mathews (41), who quit the captaincy this week after Sri Lanka's loss in the one-day series against Zimbabwe.
Cremer, who had got Kusal Mendis caught behind for 11 before tea, struck twice in the final session of play to put the hosts in trouble at 238-6.
Dilruwan Perera, who made a gritty 33 with 2 fours and as many sixes, was run out after hesitating on a single with his hamstrung partner Gunaratne.
Another unlucky run out early in the innings saw the back of opening batsman Upul Tharanga, who gave Sri Lanka a solid start with his brisk 71.
Tharanga fell short of his crease while backing up to a straight drive by Chandimal as the ball grazed past the fingers of paceman Donald Tiripano.
Tiripano's lucky fielding effort came after he got Zimbabwe's first breakthrough in Dimuth Karunaratne (25) in his first over after lunch, ending an 84-run opening partnership.
Earlier the Zimbabwe innings lasted just 4.4 overs of the morning session, adding only 12 runs to their overnight score. Batsman Craig Ervine top-scored with 160.
Left-arm spinner Herath returned with an impressive 5-116, his 30th five-wicket haul in 81 Tests.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.